CoChat

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

Open access

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Abstract

Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in a variety of tumour cells through activation of TRAIL-R1 and TRAIL-R2 death signalling receptors. Here, we describe the characterisation and activity of HGS-ETR1, the first fully human, agonistic TRAIL-R1 mAb that is being developed as an antitumour therapeutic agent. HGS-ETR1 showed specific binding to TRAIL-R1 receptor. HGS-ETR1 reduced the viability of multiple types of tumour cells in vitro, and induced activation of caspase 8, Bid, caspase 9, caspase 3, and cleavage of PARP, indicating activation of TRAIL-R1 alone was sufficient to induce both extrinsic and intrinsic apoptotic pathways. Treatment of cell lines in vitro with HGS-ETR1 enhanced the cytotoxicity of chemotherapeutic agents (camptothecin, cisplatin, carboplatin, or 5-fluorouracil) even in tumour cell lines that were not sensitive to HGS-ETR1 alone. In vivo administration of HGS-ETR1 resulted in rapid tumour regression or repression of tumour growth in pre-established colon, non-small-cell lung, and renal tumours in xenograft models. Combination of HGS-ETR1 with chemotherapeutic agents (topotecan, 5-fluorouracil, and irinotecan) in three independent colon cancer xenograft models resulted in an enhanced antitumour efficacy compared to either agent alone. Pharmacokinetic studies in the mouse following intravenous injection showed that HGS-ETR1 serum concentrations were biphasic with a terminal half-life of 6.9-8.7 days and a steady-state volume of distribution of approximately 60 ml kg(-1). Clearance was 3.6-5.7 ml(-1) day(-1) kg(-1). These data suggest that HGS-ETR1 is a specific and potent antitumour agent with favourable pharmacokinetic characteristics and the potential to provide therapeutic benefit for a broad range of human malignancies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6602487

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Characterization and specificity of HGS-ETR1 antibody. (A) Direct-binding ELISA data show the binding of indicated concentrations of HGS-ETR1 to the TRAIL-R1 extracellular domain Fc-protein (filled circles) or other TRAIL-R extracellular domain Fc-proteins (open symbols) immobilised on 96-well plates. Binding of HGS-ETR1 to TRAIL-receptors was detected using anti-human Fab-peroxidase conjugate. (B) Binding of HGS-ETR1 to SW480 cells analysed by flow cytometry. The top panel shows the binding of isotype control monoclonal antibody (IC mAb, dotted line) and HGS-ETR1 (shaded peak). The bottom panels show the binding of HGS-ETR1 alone (shaded peak) or binding of HGS-ETR1 in presence of 5 μg ml−1 of the indicated soluble TRAIL-R Fc-protein (solid line). (C) For viability assays, SW480 cells were plated at 1 × 104 cells well−1 in a 96-well plate and cultured overnight. A 1 μg ml−1 concentration of HGS-ETR1 or isotype control monoclonal antibody (IC mAb) was added to the cells in the absence or presence of the indicated soluble TRAIL-receptor proteins (sTRAIL-R1-4, sOPG, 5 μg ml−1) and cell viability, measured as relative light units (RLU), was determined after 48 h. Data is the mean±s.d. of triplicate samples.
Figure 1 Characterization and specificity of HGS-ETR1 antibody. (A) Direct-binding ELISA data show the binding of indicated concentrations of HGS-ETR1 to the TRAIL-R1 extracellular domain Fc-protein (filled circles) or other TRAIL-R extracellular domain Fc-proteins (open symbols) immobilised on 96-well plates. Binding of HGS-ETR1 to TRAIL-receptors was detected using anti-human Fab-peroxidase conjugate. (B) Binding of HGS-ETR1 to SW480 cells analysed by flow cytometry. The top panel shows the binding of isotype control monoclonal antibody (IC mAb, dotted line) and HGS-ETR1 (shaded peak). The bottom panels show the binding of HGS-ETR1 alone (shaded peak) or binding of HGS-ETR1 in presence of 5 μg ml−1 of the indicated soluble TRAIL-R Fc-protein (solid line). (C) For viability assays, SW480 cells were plated at 1 × 104 cells well−1 in a 96-well plate and cultured overnight. A 1 μg ml−1 concentration of HGS-ETR1 or isotype control monoclonal antibody (IC mAb) was added to the cells in the absence or presence of the indicated soluble TRAIL-receptor proteins (sTRAIL-R1-4, sOPG, 5 μg ml−1) and cell viability, measured as relative light units (RLU), was determined after 48 h. Data is the mean±s.d. of triplicate samples.CC BY · PubMed Central
Figure 2 HGS-ETR1 induces tumour cell killing and apoptotic signalling. (A) SW480, Colo205, HCT116, H2122, H460, SU.86.86. RL95-2, ST486, JURL-MK1, A498, SNU398, and WM793B cells were plated in 96-well plates at approximately 1 × 104 cells well−1, and cultured overnight. Indicated concentrations of HGS-ETR1 (closed circles), or isotype control antibody (IC mAb, open squares) were added and cell viability, measured as relative light units (RLU), was determined after 48 h. (B) Cells were treated as in viability assays (ng ml−1) and caspase 3/7 activity was measured as relative fluorescent units (RFU) after 6 h of treatment. The viability and caspase data are the mean±s.d. of triplicate samples from matching representative experiments. (C) ST486, SW480, and HCT116 cells were plated on 100-mm plates, cultured overnight and indicated concentrations of HGS-ETR1 or isotype control antibody (10 μg ml−1) were added. After 4 h of treatment, cell lysates were prepared, normalised for protein concentration and Western analysis was performed. The actin protein levels are shown as a control for protein loading.
Figure 2 HGS-ETR1 induces tumour cell killing and apoptotic signalling. (A) SW480, Colo205, HCT116, H2122, H460, SU.86.86. RL95-2, ST486, JURL-MK1, A498, SNU398, and WM793B cells were plated in 96-well plates at approximately 1 × 104 cells well−1, and cultured overnight. Indicated concentrations of HGS-ETR1 (closed circles), or isotype control antibody (IC mAb, open squares) were added and cell viability, measured as relative light units (RLU), was determined after 48 h. (B) Cells were treated as in viability assays (ng ml−1) and caspase 3/7 activity was measured as relative fluorescent units (RFU) after 6 h of treatment. The viability and caspase data are the mean±s.d. of triplicate samples from matching representative experiments. (C) ST486, SW480, and HCT116 cells were plated on 100-mm plates, cultured overnight and indicated concentrations of HGS-ETR1 or isotype control antibody (10 μg ml−1) were added. After 4 h of treatment, cell lysates were prepared, normalised for protein concentration and Western analysis was performed. The actin protein levels are shown as a control for protein loading.CC BY · PubMed Central
Figure 3 Combination of HGS-ETR1 with chemotherapeutic agents enhances tumour cell killing in vitro. HCT116, H460, ES2, and TTn cells were plated in 96-well plates at approximately 1 × 104 cells well−1 and cultured overnight. Indicated concentrations of HGS-ETR1 (closed circles), isotype control antibody (IC mAb, open upward triangles); HGS-ETR1 plus indicated chemotherapeutic drug (closed squares), or IC mAb plus chemotherapeutic drug (open downward triangles) were added and cell viability, measured as relative light units (RLU), was determined after 48 h of treatment. Data are the mean±s.d. of triplicate samples.
Figure 3 Combination of HGS-ETR1 with chemotherapeutic agents enhances tumour cell killing in vitro. HCT116, H460, ES2, and TTn cells were plated in 96-well plates at approximately 1 × 104 cells well−1 and cultured overnight. Indicated concentrations of HGS-ETR1 (closed circles), isotype control antibody (IC mAb, open upward triangles); HGS-ETR1 plus indicated chemotherapeutic drug (closed squares), or IC mAb plus chemotherapeutic drug (open downward triangles) were added and cell viability, measured as relative light units (RLU), was determined after 48 h of treatment. Data are the mean±s.d. of triplicate samples.CC BY · PubMed Central
Figure 4 HGS-ETR1 represses the growth of lung, colon, and renal tumours in vivo. Athymic mice were injected s.c. at day 0 with H2122 (A), Colo205 (B), or A498 (C) tumour cells. After tumours had reached approximately 100 mm3, mice were administered isotype control monoclonal antibody (IC mAb, open squares) or HGS-ETR1 (circles) by i.v. injection at the indicated times (arrows) and doses. Eight to 10 mice were included in each group. Each time point represents the mean value (±s.e.m.) of the tumour sizes within the treatment group on the day of measurement.
Figure 4 HGS-ETR1 represses the growth of lung, colon, and renal tumours in vivo. Athymic mice were injected s.c. at day 0 with H2122 (A), Colo205 (B), or A498 (C) tumour cells. After tumours had reached approximately 100 mm3, mice were administered isotype control monoclonal antibody (IC mAb, open squares) or HGS-ETR1 (circles) by i.v. injection at the indicated times (arrows) and doses. Eight to 10 mice were included in each group. Each time point represents the mean value (±s.e.m.) of the tumour sizes within the treatment group on the day of measurement.CC BY · PubMed Central
Figure 5 Enhanced antitumour effect by combination of chemotherapeutic agents and HGS-ETR1. Athymic mice were injected s.c. on day 0 with tumour cells. For the Colo205 and HCT116 models, tumours were allowed to grow to approximately 100 mm3 before treatment. Chemotherapeutic agents, isotype control monoclonal antibody (IC mAb), or HGS-ETR1 were administered at the indicated times (arrows) and concentrations. Eight to 10 mice were included in each group. For the SW480 de novo model, a loading dose of HGS-ETR1 (20 mg kg−1) was administered i.v. on day 1. Topotecan was administered i.p. at a dose of 0.3 mg kg−1 on days 1–3. Subsequently, HGS-ETR1 (10 mg kg−1) and topotecan (0.3 mg kg−1) were administered i.p. on days 4, 7, 10, 13, and 16. One group of control mice was injected only with vehicle control. Six mice were included in each group. For all models, each time point represents the mean value (±s.e.m.) of the tumour sizes within the treatment group on the day of measurement.
Figure 5 Enhanced antitumour effect by combination of chemotherapeutic agents and HGS-ETR1. Athymic mice were injected s.c. on day 0 with tumour cells. For the Colo205 and HCT116 models, tumours were allowed to grow to approximately 100 mm3 before treatment. Chemotherapeutic agents, isotype control monoclonal antibody (IC mAb), or HGS-ETR1 were administered at the indicated times (arrows) and concentrations. Eight to 10 mice were included in each group. For the SW480 de novo model, a loading dose of HGS-ETR1 (20 mg kg−1) was administered i.v. on day 1. Topotecan was administered i.p. at a dose of 0.3 mg kg−1 on days 1–3. Subsequently, HGS-ETR1 (10 mg kg−1) and topotecan (0.3 mg kg−1) were administered i.p. on days 4, 7, 10, 13, and 16. One group of control mice was injected only with vehicle control. Six mice were included in each group. For all models, each time point represents the mean value (±s.e.m.) of the tumour sizes within the treatment group on the day of measurement.CC BY · PubMed Central
Figure 6 Pharmacokinetics of HGS-ETR1 in mice. Serum concentrations of HGS-ETR1 were determined in BALB/c mice following i.v. injection of 10 or 20 mg kg−1. Male BALB/c mice were injected i.v. with either 10 or 20 mg kg−1 HGS-ETR1, and serum concentrations were followed for 10 days. Data points are the mean (±s.d.) and solid lines represent the fit of a two-compartment pharmacokinetic model to the data.
Figure 6 Pharmacokinetics of HGS-ETR1 in mice. Serum concentrations of HGS-ETR1 were determined in BALB/c mice following i.v. injection of 10 or 20 mg kg−1. Male BALB/c mice were injected i.v. with either 10 or 20 mg kg−1 HGS-ETR1, and serum concentrations were followed for 10 days. Data points are the mean (±s.d.) and solid lines represent the fit of a two-compartment pharmacokinetic model to the data.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Cited by

See all 306

Metadata

Authors
Pukac, L., Kanakaraj, P., Humphreys, R., Alderson, R., Bloom, M., Sung, C., Riccobene, T., Johnson, R., Fiscella, M., Mahoney, A., Carrell, J., Boyd, E., Yao, X. T., Zhang, L., Zhong, L., von Kerczek, A., Shepard, L., Vaughan, T., Edwards, B., Dobson, C., Salcedo, T., & Albert, V
Affiliations
  • Human Genome Sciences (United States) (US)
  • Recombinant Antibody Technology (United Kingdom) (GB)
Corresponding author
Pukac, L
Venue
British Journal of Cancer
Published
2005-04
Volume
92
Issue
8
Pages
1430-1441
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W1974144614
Cited by
306
References
56
Citations by year
2025: 6 · 2024: 6 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 5 · 2019: 11 · 2018: 3 · 2017: 8 · 2016: 8 · 2015: 12 · 2014: 7 · 2013: 13 · 2012: 16
FWCI
14.68
Type
journal article
Language
en
Open access
Locations
  • British Journal of Cancer (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords
TRAIL-R1, TRAIL receptor 1, agonistic monoclonal antibody, TRAIL, apoptosis, caspase activation, PARP cleavage, combination chemotherapy, colon cancer, non-small cell lung cancer, renal tumours, xenograft models, pharmacokinetics, cancer therapy
MeSH terms
Animals, Antibodies, Monoclonal, Antibody Specificity, Antineoplastic Agents, Enzyme-Linked Immunosorbent Assay, Female, Flow Cytometry, Half-Life, Humans, Male, Mice, Nude, Neoplasms, Experimental, Blotting, Western, Apoptosis, Receptors, Tumor Necrosis Factor, Cell Line, Tumor, Mice, Receptors, TNF-Related Apoptosis-Inducing Ligand

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. https://app.cochat.ai/papers/10.1038/sj.bjc.6602487
The paper
Pukac, L., Kanakaraj, P., Humphreys, R., Alderson, R., Bloom, M., Sung, C., Riccobene, T., Johnson, R., Fiscella, M., Mahoney, A., Carrell, J., Boyd, E., Yao, X. T., Zhang, L., Zhong, L., von Kerczek, A., Shepard, L., Vaughan, T., Edwards, B., . . . Albert, V. (2005). HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6602487

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.